Integral Health Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-500,000
Closed -$12.7M 99
2025
Q3
$12.7M Sell
500,000
-200,000
-29% -$4.94M 0.86% 36
2025
Q2
$17M Buy
700,000
+400,000
+133% +$9.33M 1.55% 24
2025
Q1
$7.6M Buy
+300,000
New +$7.85M 0.81% 36
2023
Q4
Sell
-150,000
Closed -$4.98M 87
2023
Q3
$4.98M Buy
+150,000
New +$5.3M 0.69% 53
2022
Q2
Sell
-300,000
Closed -$15.5M 80
2022
Q1
$15.5M Buy
300,000
+100,000
+50% +$5.19M 4.04% 3
2021
Q4
$11.8M Sell
200,000
-50,000
-20% -$2.48M 3.27% 8
2021
Q3
$10.8M Buy
+250,000
New +$11.1M 3.09% 7

Other funds holding PFE

Integral Health Asset Management's PFE Position: Q4 2025 in Review

Integral Health Asset Management sold out of Pfizer (PFE) in Q4 2025, closing a stake of 500,000 shares — an estimated $12.7M sold.

Integral Health Asset Management first reported a position in PFE in Q3 2021 and held it in 7 quarters. The position peaked at $17M in Q2 2025. 2,915 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Integral Health Asset Management reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
  • Integral Health Asset Management sold 500,000 Pfizer shares in Q4 2025, an estimated $12.7M.
  • Integral Health Asset Management first reported a position in Pfizer in Q3 2021 and held it in 7 quarters.
  • Integral Health Asset Management's Pfizer position peaked at $17M in Q2 2025.
  • 2,915 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Integral Health Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.